Evidence map›Paper›PMID 38428357›Full record

ArticleBiologicals : journal of the International Association of Biological Standardization2024

Report for the Eighth Asian National Control Laboratory Network meeting in 2023: Self-sufficiency strategy of plasma-derived medicinal products and regulatory harmonisation.

Chan Woong Choi, Youngju Choi, Yuyun Siti Maryuningsih, Bayu Wibisono, Jong Won Kim, Dio Ramondrana, Takuo Mizukami, Masaki Ochiai, Azraini Abdul Samat, Caren Mangorangca and 5 more

Abstract read
In one paragraph

Article in Biologicals : journal of the International Association of Biological Standardization, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Chan Woong ChoiBlood Products Division, Biopharmaceutical & Herbal Medicine Evaluation Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju, South Korea.
Youngju ChoiBiopharmaceutical & Herbal Medicine Evaluation Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju, South Korea.
Yuyun Siti MaryuningsihBlood and Other Product of Human Origin, Health Products Policy and Standards Department, World Health Organization Headquarters, Geneva, Switzerland.
Bayu WibisonoIndonesian Food and Drug Authority, Jakarta, Indonesia.
Jong Won KimVaccines Division, Biopharmaceutical & Herbal Medicine Evaluation Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju, South Korea.
Dio RamondranaIndonesian Food and Drug Authority, Jakarta, Indonesia.
Takuo MizukamiNational Institute of Infectious Diseases, Tokyo, Japan.
Masaki OchiaiNational Institute of Infectious Diseases, Tokyo, Japan.
Azraini Abdul SamatNational Pharmaceutical Regulatory Agency, Selangor, Malaysia.
Caren MangorangcaFood and Drug Administration Philippines, Muntinlupa City, Philippines.
Dung Luu ThiNational Institute for Control of Vaccines and Biologicals, Ha Noi, Viet Nam.
Hung Pham VanNational Institute for Control of Vaccines and Biologicals, Ha Noi, Viet Nam.
Sun Bo ShimBlood Products Division, Biopharmaceutical & Herbal Medicine Evaluation Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju, South Korea.
Su Kyoung SeongBlood Products Division, Biopharmaceutical & Herbal Medicine Evaluation Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju, South Korea.
In Soo ShinBlood Products Division, Biopharmaceutical & Herbal Medicine Evaluation Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju, South Korea. Electronic address: kshin33@korea.kr.

Funding

World Health Organization 001
6 · The paper itself

Abstract

The Eighth Asian National Control Laboratory (NCL) Network meeting, entitled "Biological Products Quality Control and Self-Sufficiency Strategy focusing on plasma-derived medicinal products (PDMPs)" was held in Seoul on 31 August 2023. The participants were NCL experts from Indonesia, Japan, Malaysia, the Philippines, Vietnam, and the Republic of Korea. Special lectures included the PDMPs self-sufficiency strategies of the World Health Organization (WHO) and Indonesian Food and Drug Authority, and a case study on Global Benchmarking Tool (GBT) assessment for vaccines by the Korea Ministry of Food and Drug Safety. The NCL delegates shared their current experiences with national lot releases and biological standardisation. The meeting contributed to a mutual understanding of the progress of the PDMPs self-sufficiency among Asian countries, the WHO's support strategies, and the NCL's plan for the preparation of the WHO GBT assessment. In the panel discussion, all participants agreed that building capacity in blood safety in the Asian region and harmonisation of relevant international regulatory requirements will support appropriate emergency preparedness, particularly source materials in the region, and will build the foundation for resolving the PDMPs supply insecurity that has worsened after the COVID-19 pandemic in some countries.

Indexed as

PandemicsAsiaHumansIndonesiaRepublic of KoreaWorld Health OrganizationBiological standardizationNational control laboratoryPlasma-derived medicinal productSelf-sufficiencyVaccine

Identifiers

PMID38428357
PMCPMC11004723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.